Lowenstein Sandler represented Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, in the closing of its previously announced public offering. The gross proceeds to Provention Bio from the offering, before deducting underwriting discounts and commissions and other expense payable by Provention Bio, were approximately $110 million.

Provention Bio will use its net proceeds from the public offering for general corporate purposes, including the continued funding of clinical development, regulatory, and manufacturing activities.

The Lowenstein deal team includes Michael J. Lerner, Steven M. Skolnick, James C. Shehan, Sarah P. Cole, and Timothy N. MacKay.

About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.